One-dose shot offers good protection, new hope against virus
Johnson & Johnson's long-awaited COVID-19 vaccine appears to protect against symptomatic illness with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. Janssen Pharmaceutica is headquartered in Beerse, Belgium and owned by Johnson & Johnson. (Cheryl Gerber/Johnson & Johnson via AP)
J&J said its vaccine works consistently in a broad range of people: A third of participants were over age 60, and more than 40% had other illnesses putting them at risk of severe COVID-19, including obesity, diabetes and HIV.
Comments
Want to comment on our stories? If you’re a subscriber, scroll down to the comments. If you’re not a subscriber, only paid subscribers can add their thoughts, so subscribe now. Our commenting policy can be viewed here.